TriSalus has a singular purpose – to create a new reason for hope among patients with liver metastases and pancreatic solid tumors.
The safety and efficacy of SD-101 have not been established by health authorities. SD-101 is investigational and has not been approved in the US or globally.
TriSalus Life Sciences was created to develop and commercialize an innovative therapeutic approach combining immunomodulation therapy or other tumor-killing agents with proprietary intravascular regional delivery to help overcome the substantial challenges associated with treating liver metastases and pancreatic solid tumors.
Founded Through Innovation
Our history began in 2018 with a purpose to innovate therapies for difficult-to-treat tumors such as pancreatic and liver metastases.
Our aim is to develop and research a multi-pronged approach to overcome the challenges of treating patients with liver metastases and pancreatic solid tumors by stimulating the immune system and delivering immuno-oncology therapies directly to the site of the disease via our proprietary delivery technologies. We are leveraging our deep expertise in product development and commercialization to study the combination of FDA cleared intravascular regional infusion systems powered by our proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology and delivery of therapeutics directly to liver metastases and pancreatic solid tumors. To date, this technology has been used in more than 15,000 procedures.
Seeking Answers for Treating Solid Tumors
Having studied liver immune cells for decades and operating on thousands of cancer patients, Steven Katz, MD, now Chief Medical Officer of TriSalus and Chairman of our Scientific Advisory Board, sought out answers to a fundamental question: How can device and therapeutic innovation enable immunotherapy success for patients with solid tumors?
His research led him to investigate the mechanisms of immunosuppression in and immunotherapy for solid tumors, where he learned of PEDD technology ─ and inspiration struck. For the next five years, he collaborated with TriSalus researching delivery technology combined with immuno-oncology therapies as he built upon his pioneering work in treatment of liver metastases and pancreatic tumors. Dr. Katz has validated this approach in multiple preclinical models and two immuno-oncology clinical trials, which have since become the basis from which TriSalus approaches its mission to redefine the treatment of solid tumors.
Bringing the Science and the Vision to Life
Today, TriSalus has identified organ-specific, validated targets with activity in the treatment of solid tumors. We are developing investigational treatments that attack solid tumors and stimulate the immune system, delivering cutting-edge therapies directly to the site of disease using our TriSalus Infusion Systems powered by PEDD technology.
In 2020, we acquired our first wholly-owned, investigational agent SD-101, a selective toll-like receptor agonist, that has shown in early studies promise in reversing immunosuppression and promoted responses to other forms of immunotherapy.1,2 We will further develop SD-101 as a treatment for liver metastases, pancreatic cancer, and other solid tumors. Additionally, through license agreements, collaborations, and joint ventures, we plan to acquire other immuno-oncology products and other tumor-killing agents that have potential advantages over currently available therapies. These initial drug candidates will be supported by both preclinical and clinical evidence.
By combining these therapies with our proven drug delivery technology, TriSalus is positioned to make great strides in the treatment of liver and pancreatic tumors, and we are passionately working toward discovering alternate ways of treating solid tumors and improving patient outcomes.
- Looi, C.K., et al. J Exp Clin Cancer Res. 2019 Apr 15;38(1):162.
Ribas A., et al. Cancer Discov. 2018;8(10):1250.